Giant spider provides promise of pain relief for IBS

Proudly supported by

  Last updated September 23, 2020 at 9:45 am


Pain blocking peptides found in the venom from a species of tarantula could help tailor pain relief treatment for people with irritable bowel syndrome.

Molecules from the venom of one of the world’s largest spiders could help researchers tailor pain blockers for people with irritable bowel syndrome (IBS).

Researchers from the University of Queensland screened 28 spiders, with the venom of the Venezuela Pinkfoot Goliath tarantula – which has a leg-span of up to 30 centimetres – showing the most promise.

The team led by Professor Richard Lewis from UQ’s Institute for Molecular Bioscience in collaboration with Flinders University’s Professor Stuart Brierley and the South Australian Health and Medical Research Institute hopes to find effective pain relief for chronic intestinal pain.

“All pains are complex but gut pain is particularly challenging to treat, and affects around 20 per cent of the world’s population,” Lewis says.

“Current drugs are failing to produce effective pain relief in many patients before side effects limit the dose that can be administered.”

The research evolved from 15 years of studying the potential of medicines developed from venoms, and is published in the journal Pain.

Spider venom contains hundreds of mini-proteins

Brierley says IBS and other gastrointestinal and bladder disorders cause chronic visceral pain – pain which affects the internal organs.

“Internal organs have a complex network of sensory nerves that have a wide array of voltage-gated ion channels and receptors to detect stimuli,” he says.

“The hypersensitivity of these nerves in disease often contributes to the development of pain.”

Also: A creepy crawly cure for Dravet syndrome

Voltage-gated ion channels open and close in response to changes across the cell membrane, with their dysfunction identified as a cause of chronic visceral pain.

Lewis says spider venoms contain hundreds of mini-proteins known as peptides that can inhibit voltage-gated ion channels from opening.

“Unfortunately these peptides aren’t completely selective for pain targets,” he says.

“Our goal was to find more specialised pain blockers that are potent and target pain sodium channels for chronic visceral pain, but not those that are active in the heart and other channels.”

Venom could hint at underlying drivers of pain

The team found two peptides isolated from the tarantula venom inhibited the most important ion channels underlying pain, with one particularly potent at reducing the sensory nerves of the bladder and colon and nearly stopping chronic visceral pain in a model of IBS.

Also: Poo transplants could be the answer for chronic bowel conditions

“We now have a really strong understanding of the structure and function of these spider venom peptides,” Lewis says.

“The highly selective ones have potential as treatments for pain, while others are useful as new research tools to allow us to understand the underlying drivers of pain in different diseases.”

More Like This

Pain relief may be found in the mud

Don’t laugh, fart science is important

About the Author

University of Queensland Newsroom
The latest and best science news from The University of Queensland

Published By

For more than a century, The University of Queensland has educated and worked with outstanding people to deliver knowledge leadership for a better world. Across our three campuses, UQ’s 7000+ staff and 51,000+ students deliver and experience unparalleled teaching, learning and research excellence that creates positive change globally.

Featured Videos